An observational study in Sickle Cell Disease, sponsored by Assiut University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Assiut University · Observational
This observational cross-sectional study aims to assess the relationship between inflammatory markers and pain intensity in adult patients with sickle cell disease. The study will evaluate inflammatory markers in patients with different clinical presentations, including steady state and vaso-occlusive crisis.
Sickle cell disease is a chronic hematological disorder characterized by recurrent complications, including painful vaso-occlusive crises. Inflammatory and hematological markers may vary according to the clinical state and may be associated with the severity of pain.
This observational cross-sectional study will evaluate adult patients with sickle cell disease presenting in different clinical states, including steady state and vaso-occlusive crisis. Clinical history and examination findings will be recorded, including pain intensity assessed using the Visual Analog Scale (VAS), type of clinical presentation, duration of crisis, and length of hospital stay when applicable.
Laboratory investigations will include complete blood count with differential, from which neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) will be calculated, as well as C-reactive protein (CRP), lactate dehydrogenase (LDH), and D-dimer. Other relevant routine laboratory investigations will also be recorded when available.
The study will assess the association between inflammatory markers and pain intensity and will compare these markers among different clinical presentations, particularly steady state and vaso-occlusive crisis. The study will also explore relationships between these markers and relevant hematological and biochemical parameters.
1,103 studies on the registry are indexed under Anemia, Sickle Cell; 235 are open to participants now.
This study's planned enrollment of 75 is below the median of 100 across 287 observational studies indexed under Anemia, Sickle Cell.
Browse Anemia, Sickle Cell studies →Assiut University is the lead sponsor of 4,916 studies on the registry; 2,113 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adult patients with confirmed sickle cell disease who present to Assiut University Hospitals during the study period. Participants will include patients in different clinical presentations, including steady state and vaso-occlusive crisis. Eligible patients will be enrolled according to the predefined inclusion and exclusion criteria.
Willingness to participate and provide informed consent.
Exclusion Criteria:
Adult patients with sickle cell disease will be evaluated according to their clinical presentation, including steady state and vaso-occlusive crisis. Clinical data, pain intensity, and relevant laboratory parameters including inflammatory and hematological markers will be assessed. No intervention will be assigned as part of the study.
To determine the association between NLR, PLR, and CRP levels and pain intensity, as assessed by the Visual Analogue Scale (VAS), among adult patients with sickle cell disease.
Pain intensity will be assessed using the Visual Analog Scale (VAS), and its association with neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein (CRP) levels will be evaluated in adult patients with sickle cell disease.
Time frame: At enrollment
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assiut University